News

Designed to modify SBMA through several mechanisms, AJ201 is currently in a Phase Ib/IIa study in the US to treat spinal and bulbar muscular atrophy (SBMA), which is

The company claimed that its 10mL presentation is the only FDA-approved ready-to-administer 10mL pre-filled syringe available. Nexus Pharmaceuticals CEO and president Usman Ahmed said: “We are pleased to

Under the collaboration, both the companies will work together for further AI and machine learning-driven efforts in therapeutic development. The partnership aims to gather insights more precisely that

Upadacitinib (RINVOQ, 45mg [induction dose] and 15mg and 30mg [maintenance doses]) is intended for those patients who have not shown adequate response, lost response or were intolerant to

Earlier, TMB-001 received orphan drug designation from the EC to treat autosomal recessive congenital ichthyosis (ARCI). Timber Pharmaceuticals chairman and CEO John Koconis said: “We are pleased to

Xspray Pharma will maintain financial and strategic control and grant exclusive commercialisation access to Eversana for supporting its Dasynoc launch. Dasynoc, pending approval from the Food and Drug

SAGE-718 is a first-in-class NMDA receptor positive allosteric modulator (PAM) as well as lead neuropsychiatric drug candidate. It is in development as a potential oral therapy for cognitive

Said to be the company’s first combination vaccine candidate, IVX-A12 targets RSV as well as hMPV, which are two of the top five causes of pneumonia in adult

The regulatory agency has ascertained that the application is sufficiently finished to allow a substantive review. Valneva, a specialty vaccine company, stated that the review is classified as